Posted on October 5, 2018

When deciding which medicines, treatments, services and programmes to fund, the primary aim should be to reduce uncertainty about expected outcomes.

It’s a year since cystic fibrosis drug Orkambi was made available in Ireland and so far, the reviews are mixed.  While of benefit to some patients (reduced exacerbations, for example) others were unable to tolerate it. Access to Orkambi did not come easily. People took to the streets, talked to Joe and pressure was put on government to fund this “miracle” drug.

Unsurprisingly, it is now acknowledged that it was not a miracle drug after all, but rather a step towards a miracle. While this is good for cystic fibrosis patients who will need treatment in the future, it is little consolation to those who need treatment now and to those whose access to other healthcare has been delayed owing to the opportunity costs of funding Orkambi.

Applications are open for 2024 now.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.